You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Fluticasone-Salmeterol Drug Combination

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Asthma Trial (mometasone furoate combination MDI 200/10 mcg BID, mometasone furoate combination MDI 400/10 mcg BID,

Completed
Has Results
  • Asthma
  • mometasone furoate combination MDI 200/10 mcg BID
  • +3 more
  • (no location specified)
Feb 7, 2022

A Retrospective rEal-life daTa Study to Assess exaceRbations and

Completed
  • COPD
  • COPD Exacerbation
    • Thessaloniki, Greece
      Papanikolaou Hospital of Thessaloniki
    Sep 7, 2022

    Asthma, COPD Trial in San Antonio (MGR001, Advair® Diskus®, Seretide™ Accuhaler™)

    Completed
    • Asthma
    • COPD
    • San Antonio, Texas
      Worldwide Clinical Trials Early Phase Services
    Feb 22, 2022

    Bioequivalence Trial in Larissa (Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals,

    Recruiting
    • Bioequivalence
    • Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
    • ADVAIR DISKUS® 500/50
    • Larissa, Thessaly, Greece
      BECRO Clinical Facility
    Aug 29, 2023

    Bioequivalence Trial in Larissa (Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals,

    Recruiting
    • Bioequivalence
    • Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
    • ADVAIR DISKUS® 250/50
    • Larissa, Thessaly, Greece
      BECRO Clinical Facility
    Aug 1, 2023

    Bioequivalence Trial (Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS

    Not yet recruiting
    • Bioequivalence
    • Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
    • ADVAIR DISKUS 100/50
    • (no location specified)
    Jan 20, 2023

    Altitude Edema Trial (Advair HFA, Placebo)

    Not yet recruiting
    • Altitude Edema
    • Advair HFA
    • Placebo
    • (no location specified)
    Sep 8, 2023

    Asthma Trial (RP - TA)

    Completed
    • Asthma
    • RP - TA
    • (no location specified)
    Jul 12, 2022

    Asthma Trial in Hackensack, New York (Fluticasone with salmeterol, Fluticasone HFA)

    Completed
    • Asthma
    • Fluticasone with salmeterol
    • +3 more
    • Hackensack, New Jersey
    • +2 more
    Oct 12, 2022

    Asthma Trial in Worldwide (QVM149 150/50/80 µg o.d., QVM149 150/50/160 µg o.d., salmeterol/fluticasone FDC 50/500 µg b.i.d.)

    Completed
    Has Results
    • Asthma
    • QVM149 150/50/80 μg o.d.
    • +2 more
    • Sofia, Bulgaria
    • +11 more
    Sep 30, 2021

    Moderate Asthma Trial in São Paulo (Administration of investigation drug, Administration of comparator)

    Not yet recruiting
    • Moderate Asthma
    • Administration of investigation drug
    • Administration of comparator
    • São Paulo, Brazil
      Eurofarma Laboratorios S.A
    Feb 9, 2023

    Asthma Trial in Athens (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals, ADVAIR

    Not yet recruiting
    • Asthma
    • Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals
    • +2 more
    • Athens, Greece
      BECRO Ltd.
    Jan 20, 2023

    Asthma Trial in Czechia (Elpenhaler active - Diskus )

    Completed
    • Asthma
    • Elpenhaler active - Diskus placebo
    • Karlovy Vary, Drahovice, Czechia
    • +4 more
    Apr 8, 2021

    Asthma Trial (QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149)

    Not yet recruiting
    • Asthma
    • (no location specified)
    Mar 18, 2023

    Seasonal Allergic Rhinitis Trial in Mississauga (Treatment A (Dymista): Fixed drug combination of azelastine HCl and fluticasone

    Completed
    • Seasonal Allergic Rhinitis
    • Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3
    • +3 more
    • Mississauga, Ontario, Canada
      Cliantha Research
    Feb 11, 2022

    COPD (COPD) Trial in Bordeaux (Seretide® Diskus® 500/550 µg, Ultibro® Breezhaler® 110/50 µg, Spiriva® Respimat® 2,5 µg)

    Completed
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Seretide® Diskus® 500/550 μg
    • +2 more
    • Bordeaux, France
      CIC-P - Centre François Magendie - G3 - Hôpital Haut-Lévêque
    Feb 8, 2022

    Bioequivalence, Asthma Trial in Larissa (Test, Reference)

    Active, not recruiting
    • Bioequivalence
    • Asthma
    • Larissa, Thessaly, Greece
      BECRO Clinical Facility
    Oct 19, 2021

    Asthma Trial in Huntington Beach, Raleigh, San Antonio (Fluticasone Propionate MDPI, Fluticasone Propionate/Salmeterol MDPI,

    Completed
    • Asthma
    • Fluticasone Propionate MDPI
    • +2 more
    • Huntington Beach, California
    • +2 more
    Nov 5, 2021

    Asthma Trial (Mometasone furoate/formoterol (MF/F) MDI, Fluticasone propionate/salmeterol (F/SC) DPI)

    Completed
    Has Results
    • Asthma
    • Mometasone furoate/formoterol (MF/F) MDI
    • Fluticasone propionate/salmeterol (F/SC) DPI
    • (no location specified)
    Feb 7, 2022

    Bioequivalence, Asthma Trial in Larissa (Test, Reference)

    Active, not recruiting
    • Bioequivalence
    • Asthma
    • Larissa, Thessaly, Greece
      BECRO Clinical Facility
    Apr 18, 2021

    COPD Trial in Adana, Istanbul (Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder, Tiotropium 18 mcg Inhalation

    Completed
    • COPD
    • Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder
    • +2 more
    • Adana, Turkey
    • +1 more
    Jun 11, 2020

    Bioequivalence Trial in Larissa (Test Product, Reference Product)

    Completed
    • Bioequivalence
    • Test Product
    • Reference Product
    • Larissa, Thessaly, Greece
      BECRO Clinical Facility
    Mar 8, 2021

    Bioequivalence Trial in Larissa (Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS®

    Completed
    • Bioequivalence
    • Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent
    • ADVAIR DISKUS® 500/50
    • Larissa, Thessaly, Greece
      BECRO Clinical Facility
    Mar 8, 2021

    Asthma Trial in Raleigh, Edmond, San Antonio (Treatment A: Fp MDPI, Treatment B: FS MDPI, Treatment C Flovent)

    Completed
    • Asthma
    • Treatment A: Fp MDPI
    • +3 more
    • Raleigh, North Carolina
    • +2 more
    Nov 6, 2021

    Asthma Trial in Worldwide (QVM149, Salmeterol/fluticasone plus tiotropium)

    Completed
    Has Results
    • Asthma
    • QVM149
    • Salmeterol/fluticasone plus tiotropium
    • Berazategui, Buenos Aires, Argentina
    • +162 more
    Oct 7, 2021